title: Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease.
authors.forename: Julie
authors.initials: J
authors.lastname: Rath
authors.forename: Christian
authors.initials: C
authors.lastname: Geisler
authors.forename: Claus B
authors.initials: CB
authors.lastname: Christiansen
authors.forename: Nina
authors.initials: N
authors.lastname: Hastrup
authors.forename: Hans O
authors.initials: HO
authors.lastname: Madsen
authors.forename: Mette K
authors.initials: MK
authors.lastname: Andersen
authors.forename: Lone B
authors.initials: LB
authors.lastname: Pedersen
authors.forename: Jesper
authors.initials: J
authors.lastname: Jurlander
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D019008:Drug Resistance, Neoplasm; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000821:virology*; D005260:Female; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014775:Virus Activation
chemical_list: D014408:Biomarkers, Tumor; D014740:Vidarabine; C024352:fludarabine